Krilogy Financial LLC Purchases 13,129 Shares of Exact Sciences Corporation $EXAS

Krilogy Financial LLC increased its position in Exact Sciences Corporation (NASDAQ:EXAS) by 30.7% during the third quarter, Holdings Channel.com reports. The firm owned 55,845 shares of the medical research company’s stock after buying an additional 13,129 shares during the quarter. Krilogy Financial LLC’s holdings in Exact Sciences were worth $3,055,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Massachusetts Financial Services Co. MA bought a new stake in Exact Sciences during the 2nd quarter valued at $157,805,000. Holocene Advisors LP grew its holdings in shares of Exact Sciences by 189.5% during the second quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock valued at $113,995,000 after buying an additional 1,404,086 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Exact Sciences by 643.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,286,595 shares of the medical research company’s stock worth $70,390,000 after acquiring an additional 1,113,459 shares in the last quarter. Norges Bank acquired a new stake in shares of Exact Sciences in the 2nd quarter worth about $48,372,000. Finally, AQR Capital Management LLC lifted its position in Exact Sciences by 73.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,753,283 shares of the medical research company’s stock valued at $93,169,000 after acquiring an additional 741,517 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Trading Up 0.1%

Shares of Exact Sciences stock opened at $103.43 on Thursday. The firm has a market cap of $19.74 billion, a PE ratio of -19.44, a P/E/G ratio of 2.44 and a beta of 1.42. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $103.54. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.72 and a quick ratio of 2.44. The stock has a fifty day moving average price of $102.02 and a 200-day moving average price of $74.98.

Analyst Ratings Changes

A number of analysts have commented on EXAS shares. Piper Sandler lowered Exact Sciences from an “overweight” rating to a “hold” rating and set a $105.00 price objective for the company. in a report on Monday, November 24th. Wolfe Research cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Robert W. Baird set a $105.00 price target on Exact Sciences in a research report on Thursday, November 20th. Canaccord Genuity Group cut Exact Sciences from a “buy” rating to a “hold” rating and raised their price objective for the company from $85.00 to $105.00 in a research note on Tuesday, November 25th. Finally, Zacks Research lowered shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Two analysts have rated the stock with a Buy rating, twenty-one have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $89.56.

Insider Transactions at Exact Sciences

In other Exact Sciences news, EVP Jacob A. Orville sold 5,000 shares of Exact Sciences stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total value of $375,000.00. Following the sale, the executive vice president owned 23,237 shares of the company’s stock, valued at approximately $1,742,775. The trade was a 17.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.20% of the company’s stock.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.